Literature DB >> 20132210

Mechanisms involved in the antinociception induced by systemic administration of guanosine in mice.

A P Schmidt1, A E Böhmer, C Schallenberger, C Antunes, R G Tavares, S T Wofchuk, E Elisabetsky, D O Souza.   

Abstract

BACKGROUND AND
PURPOSE: It is well known that adenine-based purines exert multiple effects on pain transmission. However, less attention has been given to the potential effects of guanine-based purines on pain transmission. The aim of this study was to investigate the effects of intraperitoneal (i.p.) and oral (p.o.) administration of guanosine on mice pain models. Additionally, investigation into the mechanisms of action of guanosine, its potential toxicity and cerebrospinal fluid (CSF) purine levels were also assessed. EXPERIMENTAL APPROACH: Mice received an i.p. or p.o. administration of vehicle (0.1 mM NaOH) or guanosine (up to 240 mg x kg(-1)) and were evaluated in several pain models. KEY
RESULTS: Guanosine produced dose-dependent antinociceptive effects in the hot-plate, glutamate, capsaicin, formalin and acetic acid models, but it was ineffective in the tail-flick test. Additionally, guanosine produced a significant inhibition of biting behaviour induced by i.t. injection of glutamate, AMPA, kainate and trans-ACPD, but not against NMDA, substance P or capsaicin. The antinociceptive effects of guanosine were prevented by selective and non-selective adenosine receptor antagonists. Systemic administration of guanosine (120 mg x kg(-1)) induced an approximately sevenfold increase on CSF guanosine levels. Guanosine prevented the increase on spinal cord glutamate uptake induced by intraplantar capsaicin. CONCLUSIONS AND IMPLICATIONS: This study provides new evidence on the mechanism of action of the antinociceptive effects after systemic administration of guanosine. These effects seem to be related to the modulation of adenosine A(1) and A(2A) receptors and non-NMDA glutamate receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132210      PMCID: PMC2848929          DOI: 10.1111/j.1476-5381.2009.00597.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  74 in total

1.  Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw.

Authors:  Alessandra Beirith; Adair R S Santos; João B Calixto
Journal:  Brain Res       Date:  2002-01-11       Impact factor: 3.252

2.  Antipsychotic-like profile of alstonine.

Authors:  L Costa-Campos; D R Lara; D S Nunes; E Elisabetsky
Journal:  Pharmacol Biochem Behav       Date:  1998-05       Impact factor: 3.533

3.  mGluR activation reveals a tonic NMDA component in inflammatory hyperalgesia.

Authors:  S J Boxall; A Berthele; T R Tölle; W Zieglgänsberger; L Urban
Journal:  Neuroreport       Date:  1998-04-20       Impact factor: 1.837

4.  Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test.

Authors:  Myung Ha Yoon; Hong Beom Bae; Jeong Il Choi
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 5.108

5.  Pharmacological profile of the potentiation of opioid analgesia by restraint stress.

Authors:  D J Calcagnetti; S W Fleetwood; S G Holtzman
Journal:  Pharmacol Biochem Behav       Date:  1990-09       Impact factor: 3.533

Review 6.  The induction of pain: an integrative review.

Authors:  M J Millan
Journal:  Prog Neurobiol       Date:  1999-01       Impact factor: 11.685

7.  The formalin test in mice: dissociation between inflammatory and non-inflammatory pain.

Authors:  Steinar Hunskaar; Kjell Hole
Journal:  Pain       Date:  1987-07       Impact factor: 6.961

8.  Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice.

Authors:  Elsa Regina Vinadé; André Prato Schmidt; Marcos Emílio Santos Frizzo; Ivan Izquierdo; Elaine Elisabetsky; Diogo Onofre Souza
Journal:  Brain Res       Date:  2003-07-04       Impact factor: 3.252

9.  Oral administration of guanosine impairs inhibitory avoidance performance in rats and mice.

Authors:  Elsa Regina Vinadé; Ivan Izquierdo; Diogo Rizzato Lara; André Prato Schmidt; Diogo Onofre Souza
Journal:  Neurobiol Learn Mem       Date:  2004-03       Impact factor: 2.877

10.  Guanosine reduces apoptosis and inflammation associated with restoration of function in rats with acute spinal cord injury.

Authors:  Shucui Jiang; Farid Bendjelloul; Patrizia Ballerini; Iolanda D'Alimonte; Elenora Nargi; Cai Jiang; Xinjie Huang; Michel P Rathbone
Journal:  Purinergic Signal       Date:  2007-09-25       Impact factor: 3.765

View more
  20 in total

1.  Guanosine Protects Against Cortical Focal Ischemia. Involvement of Inflammatory Response.

Authors:  Gisele Hansel; André Comiran Tonon; Felipe Lhywinskh Guella; Letícia Ferreira Pettenuzzo; Thiago Duarte; Marta Maria Medeiros Frescura Duarte; Jean Pierre Oses; Matilde Achaval; Diogo Onofre Souza
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  The antidepressant-like effect of guanosine is dependent on GSK-3β inhibition and activation of MAPK/ERK and Nrf2/heme oxygenase-1 signaling pathways.

Authors:  Priscila B Rosa; Luis E B Bettio; Vivian B Neis; Morgana Moretti; Isabel Werle; Rodrigo B Leal; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2019-11-25       Impact factor: 3.765

3.  Changes in Purines Concentration in the Cerebrospinal Fluid of Pregnant Women Experiencing Pain During Active Labor.

Authors:  André P Schmidt; Ana E Böhmer; Gisele Hansel; Félix A Soares; Jean P Oses; Alex T Giordani; Irimar P Posso; José Otávio C Auler; Florentino F Mendes; Elaine A Félix; Luís V Portela; Diogo O Souza
Journal:  Neurochem Res       Date:  2015-09-25       Impact factor: 3.996

4.  Neuroprotective Effects of Guanosine Administration on In Vivo Cortical Focal Ischemia in Female and Male Wistar Rats.

Authors:  Luciele Varaschini Teixeira; Roberto Farina Almeida; Francieli Rohden; Leo Anderson Meira Martins; Poli Mara Spritzer; Diogo Onofre Gomes de Souza
Journal:  Neurochem Res       Date:  2018-05-31       Impact factor: 3.996

5.  Involvement of adenosine A1 and A2A receptors on guanosine-mediated anti-tremor effects in reserpinized mice.

Authors:  C M Massari; L C Constantino; N F Marques; L B Binder; M Valle-León; M López-Cano; V Fernández-Dueñas; F Ciruela; C I Tasca
Journal:  Purinergic Signal       Date:  2020-07-28       Impact factor: 3.765

Review 6.  Neuroprotective Effects of Guanosine in Ischemic Stroke-Small Steps towards Effective Therapy.

Authors:  Karol Chojnowski; Mikolaj Opielka; Wojciech Nazar; Przemyslaw Kowianski; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

7.  Intranasal guanosine administration presents a wide therapeutic time window to reduce brain damage induced by permanent ischemia in rats.

Authors:  Denise Barbosa Ramos; Gabriel Cardozo Muller; Guilherme Botter Maio Rocha; Gustavo Hirata Dellavia; Roberto Farina Almeida; Leticia Ferreira Pettenuzzo; Samanta Oliveira Loureiro; Gisele Hansel; Ângelo Cássio Magalhães Horn; Diogo Onofre Souza; Marcelo Ganzella
Journal:  Purinergic Signal       Date:  2015-12-23       Impact factor: 3.765

8.  Neuroprotective effects of guanosine administration on behavioral, brain activity, neurochemical and redox parameters in a rat model of chronic hepatic encephalopathy.

Authors:  L G Paniz; M E Calcagnotto; P Pandolfo; D G Machado; G F Santos; G Hansel; R F Almeida; R S Bruch; L M Brum; F V Torres; A M de Assis; E P Rico; D O Souza
Journal:  Metab Brain Dis       Date:  2014-05-01       Impact factor: 3.584

9.  Extracellular guanosine regulates extracellular adenosine levels.

Authors:  Edwin K Jackson; Dongmei Cheng; Travis C Jackson; Jonathan D Verrier; Delbert G Gillespie
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-12       Impact factor: 4.249

10.  Guanosine Anxiolytic-Like Effect Involves Adenosinergic and Glutamatergic Neurotransmitter Systems.

Authors:  Roberto Farina Almeida; Daniel Diniz Comasseto; Denise Barbosa Ramos; Gisele Hansel; Eduardo R Zimmer; Samanta Oliveira Loureiro; Marcelo Ganzella; Diogo Onofre Souza
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.